NRXS earnings analysis
What we found in NRXS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include the quarterly income statement, balance sheet, cash flow statement, or segment disclosures, so current-period financial metrics cannot be verified from the filing text supplied. The principal signal is negative: disclosure controls remained ineffective as of June 30, 2026, with 4 continuing material weaknesses. Remediation is ongoing through the remainder of 2026, while the Company retains a potential approximately $2,000,000 patent claim and $375,000 of settlement obligations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Internal-control remediation continued
- Management continued remediation during the quarter by implementing customer acceptance procedures, developing standard vendor contract templates, enhancing disaster recovery and backup procedures, and continuing independent control testing. Testing is expected to continue through the remainder of 2026.
- Legal settlement obligation declining
- The previously disclosed $750,000 settlement had $375,000 remaining payable as of June 30, 2026, reducing the outstanding legal settlement obligation from its original amount.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ineffective disclosure controls persist
- Disclosure controls and procedures were concluded to be ineffective as of June 30, 2026. The filing identifies 4 continuing material weaknesses, including ineffective approval processes, inadequate contract management, U.S. GAAP misapplication, and ineffective disclosure controls.
- Unresolved patent compensation claim
- The Company remains exposed to a patent compensation claim of approximately $2,000,000 related to U.S. Patent No. 10,413,719. Management disputes the claim, but states the matter is in its early stages and the outcome cannot be predicted.
- Remaining litigation settlement payments
- The Company still owed $375,000 under a $750,000 settlement as of June 30, 2026, payable in 12 equal monthly installments beginning in January 2026; the remaining payments create an ongoing liquidity obligation.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the 10-Q. The filing states that independent control testing is expected to continue through the remainder of 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- Neuraxis, Inc. reported Q1 2026 results showing a significant increase in revenue and gross profit compared to the same period last year, with revenues of approximately $1.6 million, marking a 78% increase from $895,655…
- 10-K · March 19, 2026
- NeurAxis reported FY2025 revenue of $3,569,282 (sum of quarterly results) driven by Q4 2025 revenue of $968,127 (up 27.2% YoY vs Q4 2024’s $761,165). Gross margin remained high (Q4 gross margin 85.4%; FY2025 weighted…
- 10-Q · November 10, 2025
- NeurAxis reported Q3 revenue of $811,414 (below the $1,000,000 estimate) — down 9.3% sequentially from $894,086 but up 21.7% year-over-year from $666,625. Gross margin remained high at 83.3% but operating loss widened…
- 10-Q · August 12, 2025
- Neuraxis reported Q2 revenue of $894,086, largely flat versus Q1 ($895,655) but up materially year-over-year from $611,500. Gross margin compressed to 83.6% while operating margin and EPS improved versus prior quarter…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NRXS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever